Short answer
COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 results for quarter ended June 30, 2026.
COLLEGIUM PHARMACEUTICAL, INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 6, 2026 and furnished as Exhibit 99.1
- Investors should review Exhibit 99.1 for financial results and management commentary
Item 7.01 · Regulation FD Disclosure
- Earnings presentation released August 6, 2026 under Regulation FD
- Exhibit 99.2 contains management’s earnings-related information and investor materials
- Presentation furnished, not filed, limiting its use in certain securities-law contexts
Item EX-99.1 · Exhibit EX-99.1
- Q2 product revenue $199.9M, up 6% YoY; JORNAY PM revenue $46.1M, up 41%, supporting ADHD growth thesis
- AZSTARYS acquisition contributed $12.9M from May 12 and lifted full-year guidance to $65–$75M
- Pain revenue fell 9% to $140.9M, with Nucynta down 24% and Xtampza down 14%, offsetting ADHD momentum
- Full-year product revenue guidance reduced to $825–$855M and adjusted EBITDA to $445–$470M, primarily from weaker Nucynta authorized-generic pricing
- GAAP net loss $15.1M versus $12.0M income; adjusted EBITDA rose 8% to $113.8M, while acquisition costs increased operating expenses 45% to $106.6M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other COLLEGIUM PHARMACEUTICAL, INC 8-K filings
Get the next COLL 8-K as it lands
Follow COLL for push alerts, or ask the research agent what this filing means.